Cellular Biomedicine Group (CBMG) Misses Q4 EPS by 1c

Cellular Biomedicine Group (NASDAQ: CBMG) reported Q4 EPS of ($0.43), $0.01 worse than the analyst estimate of ($0.42). Revenue for the quarter came in at $620.2 thousand versus the consensus estimate of $1.5 million.

For earnings history and earnings-related data on Cellular Biomedicine Group (CBMG) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c